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Baicalin is one of the major bioactive constituents of Scutellariae Radix, but the biotransformation of it is poorly understood. In
this paper, the metabolism of baicalin in rat was studied. Nine metabolites including one new compound were isolated and
identiﬁed structurally. The plausible scheme for the biotransformation pathways of baicalin in the rats was deduced. And the
main metabolites were evaluated for their antioxidation and anti-inﬂammation biological activities for the ﬁrst time.
1.Introduction
Scutellariae Radix, the root of Scutellariae baicalensis Georgi,
is widely used in traditional Chinese formulations. Baicalin
(baicalein 7-O-glucuronide) is one of the major bioactive
constituents of it, which possesses antiallergic, anti-inﬂam-
matory activity and antioxidation and has been used for the
treatment of hepatitis, hyperlipidemia, and lipolysis [1].
It is well known that the process of drug metabolism af-
fects therapeutic eﬀects of drug. The biotransformation of
baicalin is poorly understood, and that is due in part to diﬃ-
culties that have been encountered in obtaining enough
amounts to identify the structure of the metabolites and
study the bioactivities of them. Although some works on the
metabolism of baicalin have been investigated with the
developmentofchromatography-spectrographictechnology,
because of the lack of metabolites quantitatively, many
questions about the biological activities of the metabolites
still remained after administration [2–5]. To gain additional
insight into its metabolism and the biological activities of
the metabolites, we isolated the metabolites from urine
and feces of rats and identiﬁed their structures on the
basis of physicochemical properties and spectroscopic data
analysis. Nine metabolites including one new compound
were obtained. At the same time, the antioxidation and anti-
inﬂammation biological activities of the metabolites were
investigated. It is the ﬁrst time that the metabolism and
the bioactivities of the metabolites of baicalin were studied
comprehensively.
2.MaterialsandMethods
2.1.Drugs. BaicalinwasisolatedandpuriﬁedfromScutellar-
iae Radix according to the method reported previously [6].
ThecrudedrugwasfurtherpuriﬁedwithopenODScolumn,
and the purity of the material exceeded 95% that was
conﬁrmed by HPLC.
2.2.DosingProcedure. Seven-weekoldWistarrats(ﬁvemales
and ﬁve females), weighing 180 to 210g, were used for the
experiments. For isolation of metabolites, the rats were
orally administered baicalin (500mg/Kg) suspended in 0.5%
CMC-Na solution with repeated dosing three times, then
urine and feces were obtained by using a metabolic cage for
48h. All samples were stored below −20◦C until use.
2.3. Isolation of Metabolites. Urine samples from rats were
combined, ﬁltrated, and adjusted to PH 4 with HCl and per-
formed by chromatographic separation on a resin column
eluting with water (partI), C2H5OH/H2O(3:7) (partII),2 Evidence-Based Complementary and Alternative Medicine
H
O
OH
COOH
HO
HO
H
H
O
O
O
O
O
H
H
H
H
OH
H
COOH H
HO
HO
H OH
H
H
H
H
H
O
O O O
OH
OH
HO
HO
H
H
H
H
H
HO
H
H
H
O
O
O O
H
H
H
H OH
OH
HO
HO
H
H
COOCH2CH3
COOCH2CH3
M2 M4
M9 H3CO
Figure 1: The NOE correlations on the NOESY spectra of metabolites M2, M4,a n dM9.
and C2H5OH/H2O (9:1) (part III). Part III was subject-
edd to ODS column eluting with CH3CN/H2O gradiently
(from 95% H2O to 65% H2O) to obtain the compounds
M1(45mg), M2(10mg), M3(5mg), and M4(3mg). Prepar-
ative HPLC on ODS column was used to further purify 70%
H2OfractionfromODScolumnwithCH3OH/CH3CN/H2O
(20:20:60) to obtain compounds M7(2mg) and M9(3mg),
and 65% H2O fraction from ODS column was also chroma-
tographed on preparative HPLC with CH3OH/H2O (70:60)
to obtain compounds M6(3mg) and M8(3mg). Preparative
TLC on silica gel was used to further purify 75% H2Of r a c -
tion from ODS column to obtain compound M5(25mg).
Feces samples from rats were combined, suspended in
the water and adjusted to PH 7 with NaHCO3-saturated
aqueoussolution,andthenﬁltrated.Theﬁltratewasadjusted
to PH 4 with HCl and subjected to a resin column eluting
with water (part I), C2H5OH-H2O( 3 : 7 )( p a r t I I ) ,a n d
C2H5OH-H2O(9:1)(partIII).ThenpartIIandpartIIIwere
combined and subjected to Sephadex LH-20 eluting with
C2H5OH-H2O (from 100% H2O to 30% H2O): C2H5OH-
H2O (2:8) fraction from LH-20 gave M1(20mg); C2H5OH-
H2O(35:65)fractiongaveM5(32mg);C2H5OH-H2O(4:6)
fraction was further puriﬁed by preparative HPLC on an
ODS column eluting with CH3OH-H2O( 2 : 8 )a n dg a v e
M6(2mg) and M8(2mg).
2.4. Identiﬁcation of Baicalin and Metabolites
2.4.1. General Experimental Procedures. Semipreparative
high-performanceliquid chromatographywasperformedon
an ODS column (YMC-pack ODS-A, 10 × 250mm, 5μm) at
a ﬂow rate of 3mL/min. Analyses of compounds by electro-
spray ionization mass (ESI-MS) spectroscopy were conduct-
ed with a Thermo-Finnigan LCQ quadrupole ion-trap mass
spectrometer (Thermo, San Jose, CA). Nuclear magnetic res-
onance (NMR) spectroscopy was performed on a BRUKER-
APX-300 to obtain 1H (300MHz) and 13C (75MHz) spectra
of the pigment in dimethyl sulfoxided-6 (DMSO-d6).
2.4.2. Metabolites Data
M2: yellow powder. ESI-MS m/z: 645.1 [M+Na]+, 623.1
[M+H]+,621.1[M-H]−,621.1[M-H]−,445.0[M-glcA-H]−.
1H-NMR (300MHz, DMSO-d6): δ7.61 (2H, m, H-3 ,5 ),
7.60 (1H, m, H-4 ), 8.10 (2H, d, J = 6.0Hz, H-2 ,6 )], 7.12
(1H, s, H-8), 7.07 (1H, s, H-3), 12.89 (1H, s, HO-5), 5.27
(1H, d, J = 7.4Hz, 7-glcA-1), 4.97 (1H, d, J = 7.3Hz, 6-
glcA-1), 4.00 (1H, d, J = 9.5Hz, 7-glcA-5), 3.57 (1H, d, J =
9.6Hz, 6-glcA-5), 3.1–3.4 (m). NOESY: given as in Figure 1.
M3: yellow powder. ESI-MS m/z: 483.1 [M+Na]+, 459.0 [M-
H]−, 445.0 [M-CH3-H]−. 1H-NMR (300MHz, DMSO-d6):
δ 7.62 (2H, m, H-3 ,5 ), 7.60 (1H, m, H-4 ), 8.08 (2H, d,
J = 6.0Hz, H-2 ,6 )], 7.06 (1H, s, H-8), 7.02 (1H, s, H-
3), 12.57(1H, s, HO-5), 8.29 (1H, s, HO-6), 5.29 (1H, d,
J = 6.9Hz, 7-glcA-1), 4.23 (1H, d, J = 9.3Hz, 7-glcA-5),
3.1–3.4 (m).
M4: yellow powder. ESI-MS m/z: 497.1 [M+Na]+, 475.1
[M+H]+, 473.0 [M-H]−, 445.0 [M-CH3CH2-H]. 1H-NMR
(300MHz, DMSO-d6): δ 7.60 (2H, m, H-3 ,5 ), 7.59 (1H, m,
H-4 ), 8.08 (2H, d, J = 6.0Hz, H-2 ,6 ), 7.07 (1H, s, H-8),
7.02 (1H, s, H-3), 12.59 (1H, s, HO-5), 8.65 (1H, s, HO-6).
5.28 (1H, d, J = 7.2Hz, 7-glcA-1), 4.18 (1H, d, J = 9.6Hz,
7-glcA-5), 3.1–3.4 (m), 1.21 (3H, t, J = 7.2Hz, CH3), 4.11
(2H, m, CH2). NOESY: given as in Figure 2.
M6: yellow powder. ESI-MS m/z: 307.0 [M+Na]+, 282.9 [M-
H]−. 1H-NMR (300MHz, DMSO-d6): δ 7.61 (2H, m, H-
3 ,5 ), 7.61 (1H, m, H-4 ), 8.07 (2H, d, J = 6.0Hz, H-2 ,6 ),
6.25 (1H, s, H-8), 6.96 (1H, s, H-3), 12.51 (1H, s, HO-5), 8.4
(1H, s, HO-6), 3.80 (3H, s, OCH3).
M7: yellow powder. ESI-MS m/z: 874.8 [3M+Na]+, 590.9
[2M+Na]+, 307.0 [M+Na]+, 282.9 [M-H]−. 1H-NMR
(300MHz, DMSO-d6): δ 7.63 (2H, m, H-3 ,5 ), 7.62 (1H,
m, H-4 ), 8.07 (2H, m, H-2 ,6 ), 6.32 (1H, s, H-8), 7.02 (1H,
s, H-3), 12.51 (1H, s, HO-5), 10.8 (1H, s, HO-7), 3.86 (3H,
s, OCH3).
M8: yellow powder. ESI-MS m/z: 307.1 [M+Na]+, 282.9
[M-H]−. 1H-NMR (300MHz, DMSO-d6): δ 7.57 (2H, m,Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: The plausible scheme for the biotransformation pathways of baicalin in the rats.
H-3 ,5 ), 7.57 (1H, m, H-4 ), 8.37 (2H, m, H-2 ,6 ), 6.54
(1H, s, H-8), 6.19 (1H, s, H-3), 8.4 (1H, s, HO-6), 3.72 (3H,
s, OCH3).
M9: yellow powder. ESI-MS m/z: 511.1 [M+Na]+, 523.0
[M+Cl]−, 487.0 [M-H]−. 1H-NMR (300MHz, DMSO-d6):
δ 7.63(2H, m, H-3 ,5 ), 7.62 (1H, m, H-4 ), 8.09 (2H, m,
H-2 ,6 ), δ 7.13 (1H, s, H-3), 7.07 (1H, s, H-8), 12.83 (1H,
s, HO-5). δ 5.36 (1H, d, J = 6.9Hz, 7-glcA-1), 4.18 (1H,
d, J = 9.6Hz, 7-glcA-5), 3.1–3.4 (m). 3.78 (3H, s, OCH3),
1.20 (3H, t, J = 6.6Hz, CH3), and 4.14, 4.11 (each 1H, dd,
J = 15.0, 6.6Hz, CH2O). NOESY: given as in Figure 3.
2.5. Biological Activities of the Metabolites
2.5.1. Antioxidation. Livers were obtained from rats and dis-
posed of the blood. Twenty g of the livers was divided into
pieces and prepared into homogenate with physiological salt
solution by reﬁner about 8000r/min and then added physi-
ological salt solution to 400mL to be 5% tissue homogenate.
Saline was used for blank; extract of ginkgo biloba leaves
injection 250mg/mL was used for positive control; baicalin
(M1) and the metabolites baicalein (M5) and baicalein 6,7-
di-O-β-glucopyranuronoside (M2) were also analyzed.
All the numbered tubes were added with 1.5mL 5% tis-
sue homogenate, reference substance ﬂavonoids extracts of
ginkgo, and metabolites of baicalin. Negative control was
physiological saline. All the tubes were incubated at 37◦Cf o r
1h, and 1.5mL 20% trichloroacetic acid was added. All the
tubes were mixed, and standing for 10min, centrifuged at
3000rpmfor10min.Thesupernatantwasaddedwith0.67%
thiobarbituric acid and heated in boring water for 10min.
The cool solution was tested on spectrophotometer at
532nm to obtain data. Based on the standard curve of mal-
onaldehyde bis(diethyl acetal), malonaldehyde (nmol/mL)
was calculated by multiplying parameter 68.89.
2.5.2.EﬀectonLPS-InducedNOYielding. Wistarrats(weight
200 to 250g) were used for experiments. The rats were de-
capitated and treated with celiac injection with 15mL
RPMI1640 culture medium. Irrigating solution was centri-
fugedat1000r/minfor10min.Thesupernatantwasdiscard-
ed. The deposition was suspended in RPMI1640 culture me-
dium(10%FBS)andincubatedfor1h,andnonadherentcell
isdiscarded.CellsonthewallwerewashedbyRPMI1640cul-
ture medium (10% FBS), dyed by nigrosine, and counted on
blood counting chamber. The cell density was adjusted to4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀects of baicalin (M1) and the metabolites baicalein
(M5) and baicalein 6,7-di-O-β-glucopyranoside (M2) on liver lipid
peroxide of rats. (1, saline; 2, extract of ginkgo biloba leaves injec
tion 250mg/mL; 3, M1 40mg/mL; 4, M1 20mg/mL; 5, M1
10mg/mL; 6, M5 20mg/mL; 7, M5 10mg/mL; 8, M5 5mg/mL;9,
M2 40mg/mL; 10, M2 20mg/mL; 11, M2 10mg/mL; ∗, P<0.01 t-
test compared with saline group).
60 × 104 cells/cm2. The cells were incubated overnight. The
culture medium was changed to serum-free medium. LPS
(lipopolysaccharide), diﬀerent metabolites of baicalin, and
L-NAME (NO synthase inhibitor) were added. After 24h of
incubation, the contents of NO2
− in medium were tested
with Griess colorimetry. Experimental results were ana-
lyzed statistically with SPSS software. L-NAME was used
for positive control; the metabolites, baicalein 6,7-di-O-β-
glucopyranuronoside (M2), baicalein 7-O-β-D-glucopyran-
uronosidemethylester(M3),baicalein(M5),and7-O-meth-
yl-baicalein (M6), were also analyzed.
3. Results andDiscussion
3.1. The Metabolism of Baicalin in Rats. Baicalin was orally
administered to rats. The collected urine and feces samples
were extracted and analyzed as described in experimental
part.Inadditiontobaicalin,atotalof8metabolitesincluding
baicalin (M1), baicalein 6,7-di-O-β-D-glucopyranuronoside
(M2), baicalein 7-O-β-D-glucopyranuronoside methyl ester
(M3), baicalein 7-O-β-D-glucopyranuronoside ethyl ester
(M4), baicalein (M5), 7-O-methyl-baicalein (M6), 6-O-
methyl-baicalein (M7), 5-O-methyl-baicalein (M8), 6-O-
methyl-baicalein-7-O-β-D-glucopyranuronoside ethyl ester
(M9) were found present in urine and 4 metabolites (M1,
M5, M6,a n dM8) in feces. The structures of metabolites
wereelucidatedbyacombinationanalysisoftheirchromato-
graphicbehavior,analysisofMS, 1HNMRdata,NOESYdata,
and spectral comparison to several reference substances.
Metabolites M1 and M5. Compared with reference substan-
ces, M1 and M5 have the same chromatographic behavior
andNMRdata.SoM1andM5wereidentiﬁedasbaicalinand
baicalein, respectively.
Metabolites M2. Compared with baicalin, there are two
groups of the data of glucuronide on the 1HNMR spectrum
of M2 [δ:5 . 2 7( 1 H ,d ,J = 7.4Hz, 7-glcA-1), 4.97 (1H, d,
J = 7.3Hz, 6-glcA-1), 4.00 (1H, d, J = 9.5Hz, 7-glcA-5),
3.57 (1H, d, J = 9.6Hz, 6-glcA-5), 3.1–3.4 (m)], and the
chemical shift of δ 8.6 (1H, s, HO-6) disappeared, but δ
12.56 (1H, s, HO-5) still can be observed. At the same time
combined with NOESY spectrum (Figure 1), the correlation
between the anomeric proton of glucuronide (δ 5.27) and
the proton of position 8 (δ 7.12) was observed. All these
showed that there were two glucuronides at the position
of C-6 and C-7. On the ESI-MS, the m/z: 645.1 [M+Na]+,
623.1 [M+H]+, 621.1 [M-H]−, 621.1 [M-H]−, 445.0 [M-
glcA-H]− was accordant. The chemical structure of M2 was
determined as baicalein 6, 7-di-O-β-glucopyranuronoside.
Metabolites M3 and M4. Compared with the 1HNMR spec-
trum of baicalin, M3 revealed considerable similarity that
therewasonegroupofthedataofglucuronidebutdiﬀeredin
one proton of methyl δ 3.61 (3H, s), and the chemical shift
of the proton at position 5 of the glucuronide was shifted to
downﬁeldby0.6,whichsuggestedtheexistenceofglucopyra-
nuronoside methyl ester. So M3 was determined as baicalein
7-O-β-D-glucopyranuronosidemethylester.OntheESI-MS,
the m/z: 483.1 [M+Na]+, 459.0 [M-H]−, 445.0 [M-CH3-H]−
was accordant. M4 showed very similar 1HNMR spectrum
with M3, except one group of ethyl data [δ:1 . 2 1( 3 H ,t ,J =
7.2Hz, CH3), 4.11 (2H, m, CH2)]. Combined with NOESY
spectrum (Figure 1), there was a correlation between the
anomeric proton of one glucuronide (δ 5.28) and the proton
of position 8 (δ 7.07), so the positions of glucuronide can
be determined that was position 7. The correlation between
the proton at position 5 of the glucuronide (δ 4.18) and the
methylproton(δ 1.21)wasalsoobserved.Thus,thestructure
of M4 was determined as baicalein 7-O-β-D-glucopyranu-
ronoside ethyl ester.
Metabolites M6, M7,a n dM8. Compared with the 1HNMR
spectrumofbaicalin,therewasnoglucuronidesignalbutone
methyl proton in these three metabolites. The molecular
weight of them (m/z: 307.1 [M+Na]+, 282.9 [M-H]−) also
showed m/z 14 more than baicalin. All of them showed
A2A’B2 coupled system for ring-C without any substituent
that was the same as baicalin. On the 1HNMR spectrum of
M6, OH-5 and OH-6 still can be observed, but OH-7 disap-
peared, and one OCH3 was observed, and at the same time
the chemical shift of the proton of position 8 was shifted to
high ﬁeld by 0.4, compared with baicalein (M5). Therefore,
thechemicalstructureof M6wasdeterminedas7-O-methyl-
baicalein. Compared with M5, δ 12.51(1H, s, HO-5) and δ
10.8(1H,s,HO-7)stillcanbeobserved,buttheprotonsignal
of HO-6 was substituted by δ 3.86 (3H, s, OCH3-6) on M7.
The chemical structure of M7 w a sd e t e r m i n e da s6 - O-
methyl-baicalein compared with reference [7]. M8 had the
diﬀerent retention characteristic with M6 and M7. On the
1HNMR spectrum of M8, the proton signal of HO-5 was
substituted by δ 3.72 (3H, s, OCH3), and the chemical shift
of the proton of position 8 shifted to high ﬁeld by 0.3, soEvidence-Based Complementary and Alternative Medicine 5
thechemicalstructureof M8wasdeterminedas5-O-methyl-
baicalein.
Metabolite M9. Compared with baicalin, M9 revealed con-
siderable similarity, but diﬀerences were that one group of
ethoxy data [δ 1.20 (3H, t, J = 6.6Hz, CH3)a n dδ 4.14,
4.11 (each 1H, dd, J = 15.0, 6.6Hz, CH2O)], one methyl
proton (δ 3.78 (3H, s, CH3)), but the active proton of OH
at position 6 disappeared. The chemical shift of the proton
at position 5 of the glucuronide shifted to downﬁeld by 0.5,
and the proton at position 5 of glucuronide (δ4.18) had
a correlation with the methyl proton of oxyethyl group (δ
1.20) combined with NOESY spectrum (Figure 1), so this
metabolite can be determined as one glucopyranuronoside
ethylester.OnNOESY,thecorrelationbetweentheanomeric
protonoftheglucuronide(δ 5.36)andtheprotonofposition
8( δ 7.07) was observed, so the positions of glucuronide
can be determined to be position 7, and the methyl proton
was at position 6. On the ESI-MS, the m/z: 511.1 [M+Na]+,
523.0 [M+Cl]−, 487.0 [M-H]− was also accordant. Thus, the
chemical structure of M9 was determined as 6-O-methyl-
baicalein-7-O-β-D-glucopyranuronoside ethyl ester. To our
knowledge, this compound was the ﬁrst time to be isolated
and identiﬁed.
Based on the structures of these metabolites, a plausible
scheme for the biotransformation pathways of baicalin in
the rats was shown in Figure 2. The results of the present
study demonstrated that the major metabolites of baicalin
were baicalin, baicalein, and glucuronide after oral admin-
istration, and at the same time, small amount of al-
kylated products were also found, which was a little different
from [4]. This may be for the more alkylation reacted on
glucuronides and aglycone with longer time. The baical-
in is very diﬃcult to be absorbed into blood directly [8]. In
the gastrointestinal tracts of rats, baicalein was hydrolyzed
intobaicaleinbyβ-glucuronidaseproducedbyintestinalbac-
teria. Thus, baicalein can be easily absorbed into blood.
Through enterohepatic circulation, baicalein was trans-
formed to glucuronides and then modiﬁed to kinds of alky-
lated glucuronides to demonstrate bioactivities.
3.2. The Biological Activities of the Metabolites. The eﬀects of
baicalin (M1) and the metabolites (M5), (M2) on liver lipid
peroxide of rats were studied as shown in Figure 3.A sc a n
be seen, baicalin (M1), baicalein (M5), and baicalein 6,7-di-
O-β-glucopyranuronoside (M2) have more stronger antiox-
idation than positive control, ﬂavonoids extract of ginkgo.
Baicalein (M5) was even much stronger.
Figure 4showedtheeﬀectofthemetabolites(M5),(M2),
(M3), and (M6) on NO yielded by macrophage. As can be
seen, LPS (10μg/mL) induced macrophage to yield NO in
24h, and positive control L-NAME can inhibit NO yielding
signiﬁcantly. Metabolites baicalein (M5) and baicalein 6,7-
di-O-β-glucopyranuronoside (M2) had signiﬁcantly inhibit-
ing eﬀect on NO yielding induced by LPS within the range
of the test content. Baicalein 7-O-β-D-glucopyranuronoside
methyl ester (M3)a n d7 - O-methyl-baicalein (M6)h a dn o
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Figure 4: The inhibition of metabolites on LPS-induced NO yield-
ing.
inhibiting eﬀect on NO yielding induced by LPS within the
range of the test content.
As described above, baicalin was metabolized to baical-
ein, glucuronide, and methylated products though metabo-
lism of intestinal bacteria and enterohepatic circulation. Al-
thoughstudiesonthemetabolismofdrugshavebeeninvesti-
gated with the development of LC-MS, the bioactivities on
metabolites are still lacking of investigation. The results of
bioactive experiments of these metabolites in our experi-
ments demonstrated that baicalein and glucuronide showed
signiﬁcant potential on antioxidation and aﬀections on LPS-
induced NO yielding compared with reference substance.
However, when substituents were replaced by alkyl, bioac-
tivity was depressed. To our knowledge, this is the ﬁrst time
that the metabolites of baicalin were investigated on the
antioxidation and anti-inﬂammation biological activities.
These results suggested though baicalein had good biological
availability, it could not be used for its instability, while
glucuronides of baicalein will be the perspective lead com-
pounds for their good stability and bioactivities.
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